IBRX
NASDAQ · Biotechnology
Immunitybio Inc
$7.32
+0.10 (+1.39%)
IBRX News7 articles
ImmunityBio's Anktiva Expansion Faces FDA Scrutiny with 2027 Decision Date
ImmunityBio's supplemental BLA for Anktiva in papillary-only bladder cancer has been accepted by the FDA, with a decision expected by Jan. 6, 2027. The company's stock traded at $7.76, down 2.8%.
ImmunityBio Secures Exclusive US Rights to Japan BCG Strain for Bladder Cancer
ImmunityBio announced exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain for bladder cancer therapy, with FDA discussions planned. Shares closed at $7.97 Friday, down 2.2%.
ImmunityBio Plunges 21% on FDA Warning Over Anktiva Marketing
ImmunityBio shares tumbled 21.1% following an FDA warning letter alleging false or misleading promotional claims about its cancer therapy Anktiva. The drug generated essentially all of the company's $113 million in 2025 revenue.
ImmunityBio Surges on NK-Cell Manufacturing Milestone, Anktiva Expansion Progress
ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.
ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.